Search for Clinical Trial Results

Juvenile Myelomonocytic Leukemia - 20 Studies Found
Status | Study |
Recruiting |
Study Name: Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) Condition: Juvenile Myelomonocytic Leukemia Date: 2005-09-09 Interventions:
|
Active, not recruiting |
Study Name: Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia Condition: Juvenile Myelomonocytic Leukemia Date: 2013-04-02 Interventions:
|
Completed |
Study Name: Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia Condition: Juvenile Myelomonocytic Leukemia Date: 2001-10-11 Interventions:
|
Terminated |
Study Name: Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation Condition: Leukemia Date: 2008-02-06 Interventions:
|
Terminated |
Study Name: Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia Condition: Leukemia Date: 2007-07-27 Interventions: Drug: Etanercept 0.8 mg/kg Subcutaneously Once A Week for 90 Days |
Active, not recruiting |
Study Name: Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia Condition:
|
Terminated |
Study Name: Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML Condition:
Interventions: |
Recruiting |
Study Name: Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) Condition:
Date: 2015-04-14 Interventions: Drug: Azacitidine Other Name: Vidaza |
Recruiting |
Study Name: Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood Condition:
Date: 2008-04-17 |
Recruiting |
Study Name: Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation Condition:
|